NemaGen Discoveries
  • Home
  • About
  • Science
  • Team
  • News
  • Careers
  • Contact
  • More
    • Home
    • About
    • Science
    • Team
    • News
    • Careers
    • Contact
NemaGen Discoveries
  • Home
  • About
  • Science
  • Team
  • News
  • Careers
  • Contact

OUR FOUNDER

Mark C. Siracusa, PhD

  Mark is an Associate Professor in the Department of Medicine and the Center for Immunity and Inflammation at Rutgers New Jersey Medical School.

 

Mark received his PhD from Johns Hopkins University in Molecular, Microbiology and Immunology and did his Post doc at the University of Pennsylvania under David Artis. 

 
Mark has published in multiple prestigious journals and has served as permanent member of the Innate Immunity and Inflammation NIH study section since 2022.  Mark has been awarded multiple grants and currently holds 3 NIH R01s as a Principle Investigator. 

Leadership

Nicholas Shubin, PhD

Chief Executive Officer

Nick received his PhD from Brown University in Pathobiology and did his postdoc at Seattle Children’s Research Institute under Adrian Piliponsky, where he focused on understanding the roles of mast cells and basophils in acute inflammatory diseases. Nick has published research in journals such as Nature Immunology and Journal of Allergy and Clinical Immunology. Before joining NemaGen, Nick worked in Business Development for an immunoassay biotechnology company.

Research Team

Jianya Peng, PhD

John Ponessa, PhD

John Ponessa, PhD

Principle Scientist

10+ years of experience in studying host immune responses. Dr. Peng leads NemaGen's in-house drug development programs.

John Ponessa, PhD

John Ponessa, PhD

John Ponessa, PhD

Postdoctoral Scientist

Dr. Ponessa leads NemaGen's carbonic anhydrase pipeline drug development program.

Scientific and business advisory board

David Artis, PhD

Martin Devenport, PhD, MBA

Martin Devenport, PhD, MBA

Director, Jill Roberts Institute for Research in Inflammatory Bowel Disease and the  Michael Kors Professor of Immunology, Department of Medicine  at Weill Cornell 

Martin Devenport, PhD, MBA

Martin Devenport, PhD, MBA

Martin Devenport, PhD, MBA

10+ years of corporate experience in the biotech industry, with experience in all aspects of drug development, including R&D, GMP manufacturing, regulatory and clinical trials

John Piwinski, PhD

Martin Devenport, PhD, MBA

Matthew Giannetti, MD

Expertise in small molecule drug discovery with over 30 years of experience in medicinal chemistry

Matthew Giannetti, MD

Adrian Piliponsky, PhD

Matthew Giannetti, MD

Associate Director of the Brigham and Women's Hospital Mastocytosis Center. Dr. Giannetti treats patients with many mast cell disorders, including systemic mastocytosis.

Adrian Piliponsky, PhD

Adrian Piliponsky, PhD

Adrian Piliponsky, PhD

University of Washington Professor and Principal Investigator within the Center for Immunity and Immunotherapeutics at Seattle Children's Research Institute. Dr. Piliponsky is a renown mast cell biology expert.

Peter Grebow, PhD

Adrian Piliponsky, PhD

Adrian Piliponsky, PhD

Former Senior Manager for many biotech companies, including Senior VP of Worldwide Business Development at Cephalon; VP, Drug Development for Rorer Central Research; and Executive VP of Research and Development at Eagle Pharmaceuticals.

Board of Directors

Mark Siracusa, PhD

Mark Siracusa, PhD

Mark Siracusa, PhD

President of NemaGen Discoveries 

James Golubieski

Mark Siracusa, PhD

Mark Siracusa, PhD

President of Foundation Venture Capital Group

Copyright © 2025 NemaGen Discoveries - All Rights Reserved.

  • Home
  • Contact